Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
SWOG Cancer Research Network
Medical College of Wisconsin
Ascentage Pharma Group Inc.
Masaryk University
OHSU Knight Cancer Institute
Hikma Pharmaceuticals LLC
Bristol-Myers Squibb
UNC Lineberger Comprehensive Cancer Center
Hospital Universitario Dr. Jose E. Gonzalez
Bristol-Myers Squibb
Milton S. Hershey Medical Center
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Barbara Ann Karmanos Cancer Institute
Jonsson Comprehensive Cancer Center
Hamad Medical Corporation
Newcastle University
Norwegian University of Science and Technology
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb
Kanto CML Study Group
National Cancer Institute (NCI)
Bristol-Myers Squibb
Kanto CML Study Group
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Bristol-Myers Squibb